Clinical analysis of thromboprophylaxis for advanced lung cancer
Objective To explore the clinical value of thromboprophylactic therapy for advanced lung cancer.Methods Eighty patients with advanced lung cancer were selected,the patients were randomly divided into the observation group(n=41)and the control group(n=39)by random number table method,the control group was given routine treat-ment,while the observation group was treated with low molecular weight heparin calcium on the basis of routine treatment,the platelet count(PLT),D-dimer(D-D),fibrinogen(FIB),prothrombin time(PT)and partially activated thromboplas-tin time(APTT)were measured before and after treatment in both groups,the occurrence of deep venous thrombosis and pulmonary embolism was also observed.Results Compared to the control group[(301.10±22.30)×109/L,(271.10±71.02)mg/L,(3.60±0.32)g/L],PLT,D-D and FIB levels after treatment in the observation group[(301.10±22.30)×109/L、(271.10±71.02)mg/L and(3.60±0.32)g/L]were significantly lower(t=15.894,P<0.001;t=8.371,P<0.001;t=5.075,P<0.001);Compared to the control group[(10.28±1.05),(24.17±0.92)s],PT and APTT after treatment in the observation group[(11.28±1.01),(25.03±3.01)s]were significantly higher(t=4.341,P<0.001;t=3.975,P<0.001);Compared to the control group(23.08%),the incidence of deep venous thrombosis in the observation group(4.88%)was lower(χ2=5.582,P=0.018).Conclusion Low molecular weight heparin calcium can effectively prevent the occurrence of thrombosis in patients with advanced lung cancer,which is worthy of clinical use.
万方数据
维普
